SLC9A1

Across TCGA pan-cancer cohorts, SLC9A1 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SLC9A1 data layer compared with 24 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SLC9A1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLC9A1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, ACC, and BLCA are the cancer types where SLC9A1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.059	0.712	<.001	48	view →
ACC	DFS	Median	All	0.046	0.753	<.001	36	view →
BLCA	DFS	Median	III,IV	0.129	0.577	<.001	24	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →
UCEC	DFS	Median	All	0.955	0.826	.017	8	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SLC9A1–HNSC (OS)

Open the HNSC breakdown →